Direct Dose Conversion: Ozempic 9 mg to Mounjaro
There is no FDA-approved 9 mg weekly dose of Ozempic (semaglutide)—the maximum approved dose is 2.4 mg weekly for weight management and 2.0 mg weekly for diabetes. If you are referring to a 2.0-2.4 mg semaglutide dose, the equivalent Mounjaro (tirzepatide) dose is 10-15 mg weekly based on comparative weight loss efficacy 1.
Understanding the Dose Equivalence
The most recent model-based analysis directly comparing these medications found:
- Semaglutide 2.4 mg weekly ≈ Tirzepatide 10 mg weekly (99.4% probability of clinical equivalence for weight loss) 1
- Semaglutide 7.2 mg weekly (investigational) ≈ Tirzepatide 15 mg weekly (94.8% probability of equivalence) 1
Since the maximum FDA-approved semaglutide dose is 2.4 mg weekly 2, the practical conversion is:
Ozempic/Wegovy 2.4 mg weekly → Mounjaro 10 mg weekly
If maximal efficacy is needed, escalate to Mounjaro 15 mg weekly (the maximum approved adult dose) 3.
Practical Switching Protocol
When transitioning from semaglutide to tirzepatide:
- Start Mounjaro at 2.5 mg weekly (the required initiation dose to minimize GI side effects) 3
- Escalate every 4 weeks: 2.5 mg → 5 mg → 7.5 mg → 10 mg → (optional) 12.5 mg → 15 mg 3
- Target dose: 10-15 mg weekly based on tolerability and clinical response
- Timing: Administer the first Mounjaro dose on the day the next semaglutide dose would have been due
Key Differences Between the Medications
Tirzepatide demonstrates superior weight loss compared to semaglutide at equivalent doses. In the SURMOUNT trials, tirzepatide 15 mg achieved 22.5% weight reduction at 72 weeks 4, while semaglutide 2.4 mg achieved 16.9% weight reduction in STEP-1 4. The dual GIP/GLP-1 receptor agonism of tirzepatide provides enhanced metabolic effects 4.
Both medications require no renal dose adjustment 2, 5, 2, making them safe across all stages of kidney function. Both carry similar cardiovascular benefits, though semaglutide has more robust MACE reduction data in the SELECT trial (20% reduction in 3-point MACE) 4.
Important Caveats
GI side effects are dose-dependent for both medications 4. The mandatory slow titration schedule for Mounjaro exists specifically to minimize nausea, vomiting, and diarrhea 3. Never skip the 2.5 mg starting dose, even when switching from semaglutide.
Individual response varies significantly. Rare cases exist where patients respond better to semaglutide than tirzepatide despite the latter's generally superior efficacy 6. If weight loss plateaus or hyperphagia persists on tirzepatide, consider switching back to semaglutide 6.
Monitor for hypoglycemia if the patient is on insulin or sulfonylureas, as both medications potentiate glucose-lowering effects 5, 7. Dose reduction of these agents may be necessary.